ORAL Surveillance MACE conclusions: So this is fair: tofacitinib acts as a CV risk factor, there are many others, we need to address CV risk in RA pts. Nevertheless, in terms of MI risk, tofa vs TNFi, if I had one CV risk factor, I know what I'd do. #ACR21 ABST0958 @RheumNow https://t.co/4Z79XtTzl9